JP2007514651A5 - - Google Patents

Download PDF

Info

Publication number
JP2007514651A5
JP2007514651A5 JP2006538100A JP2006538100A JP2007514651A5 JP 2007514651 A5 JP2007514651 A5 JP 2007514651A5 JP 2006538100 A JP2006538100 A JP 2006538100A JP 2006538100 A JP2006538100 A JP 2006538100A JP 2007514651 A5 JP2007514651 A5 JP 2007514651A5
Authority
JP
Japan
Prior art keywords
agent
ccx
ckr2
seq
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2006538100A
Other languages
English (en)
Other versions
JP4755107B2 (ja
JP2007514651A (ja
Filing date
Publication date
Priority claimed from US10/698,541 external-priority patent/US7253007B2/en
Priority claimed from US10/912,638 external-priority patent/US7871619B2/en
Application filed filed Critical
Publication of JP2007514651A publication Critical patent/JP2007514651A/ja
Publication of JP2007514651A5 publication Critical patent/JP2007514651A5/ja
Application granted granted Critical
Publication of JP4755107B2 publication Critical patent/JP4755107B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Claims (9)

  1. 細胞上でCCX-CKR2に結合する作用物質を同定する方法であって、
    複数の作用物質を、配列番号：2の細胞外ドメインと少なくとも95％同一である細胞外ドメインを含むCCX-CKR2ポリペプチド、またはそのSDF1もしくはI-TAC結合性断片に接触させる段階、および
    CCX-CKR2ポリペプチドまたはその断片への結合に関してI-TACまたはSDF1と競合する作用物質を選択し、それによって細胞上でCCX-CKR2に結合する作用物質を同定する段階
    を含む方法。
  2. 作用物質が1,500ダルトン未満である、請求項1記載の方法。
  3. 作用物質が抗体である、請求項1記載の方法。
  4. 癌細胞の有無を決定する方法であって、
    細胞を含む試料を、配列番号：2と特異的に結合する作用物質と接触させる段階、および
    試料中のポリペプチドへの作用物質の結合を検出する段階であって、ここで試料への作用物質の結合が癌細胞の存在を示すものである段階
    を含む方法。
  5. 癌を有する個体の診断または予後を提供する方法であって、
    個体の細胞においてCCX-CKR2ポリペプチドをコードするポリヌクレオチドの発現の有無を検出する段階を含み、ここでCCX-CKR2ポリペプチドはI-TACおよび／またはSDF1に結合し、CCX-CKR2ポリペプチドは配列番号：2と少なくとも95％同一であり、それによって個体における癌を診断する方法。
  6. 配列番号：2への結合に関してSDF1およびI-TACと特異的に競合する抗体。
  7. 細胞を、インビトロで配列番号：2に特異的に結合する作用物質と接触させる段階を含み、ここで作用物質はCCX-CKR2ポリペプチドへの結合に関してSDF-1およびI-TACと競合し、細胞は配列番号：2の細胞外ドメインと少なくとも95％同一である細胞外ドメインを含むCCX-CKR2ポリペプチドを発現し、それにより作用物質を細胞上でCCX-CKR2ポリペプチドに結合させる方法。
  8. 個体において癌を処置するための医薬の製造における、CCX-CKR2ポリヌクレオチドの発現を阻害する治療有効量のポリヌクレオチドを含む化合物の使用。
  9. 個体において癌を処置するための医薬の製造における、配列番号：2への結合に関してSDF1およびI-TACと競合する治療有効量の作用物質を含む化合物の使用。
JP2006538100A 2003-10-30 2004-10-19 ケモカイン受容体に関連する疾患および状態を検出および処置するための組成物および方法 Active JP4755107B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US10/698,541 US7253007B2 (en) 2001-11-30 2003-10-30 Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors
US10/698,541 2003-10-30
US10/912,638 2004-08-04
US10/912,638 US7871619B2 (en) 2001-11-30 2004-08-04 Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors
PCT/US2004/034807 WO2005044792A2 (en) 2003-10-30 2004-10-19 Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors

Publications (3)

Publication Number Publication Date
JP2007514651A JP2007514651A (ja) 2007-06-07
JP2007514651A5 true JP2007514651A5 (ja) 2007-09-13
JP4755107B2 JP4755107B2 (ja) 2011-08-24

Family

ID=34577164

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006538100A Active JP4755107B2 (ja) 2003-10-30 2004-10-19 ケモカイン受容体に関連する疾患および状態を検出および処置するための組成物および方法

Country Status (11)

Country Link
US (2) US7871619B2 (ja)
EP (1) EP1692102B1 (ja)
JP (1) JP4755107B2 (ja)
KR (1) KR101184264B1 (ja)
AU (1) AU2004287793B2 (ja)
CA (1) CA2543115C (ja)
DK (1) DK1692102T3 (ja)
ES (1) ES2399403T3 (ja)
HK (1) HK1094203A1 (ja)
PL (1) PL1692102T3 (ja)
WO (1) WO2005044792A2 (ja)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006078780A2 (en) * 2005-01-19 2006-07-27 Genzyme Corporation Rdc1 antibodies for the diagnosis of nsclc
EP1871804B1 (en) * 2005-04-21 2013-08-28 ChemoCentryx, Inc. Antibodies that bind ccx-ckr2
ATE510929T1 (de) * 2005-06-08 2011-06-15 Hitachi Chemical Res Ct Inc Verfahren zur vorhersage einer immunantwort auf eine tumorerkrankung auf der grundlage eines mrna-expressionsprofils in tumorzellen und stimulierten leukozyten
JP2009501156A (ja) * 2005-06-29 2009-01-15 ケモセントリックス，インコーポレイティド 置換ｎ−シンナミルベンズアミド
ATE518011T1 (de) 2006-04-07 2011-08-15 Hitachi Chemical Co Ltd Erhöhte expression von t- zellenrezeptorvermittelter tumornekrosefaktorsuperfamilie und chemokin-mrna in peripheren blut leukozyten bei patienten mit morbus& xa;crohn
WO2009138519A1 (en) 2008-05-16 2009-11-19 Ablynx Nv AMINO ACID SEQUENCES DIRECTED AGAINST CXCR4 AND OTHER GPCRs AND COMPOUNDS COMPRISING THE SAME
US9512236B2 (en) 2006-12-19 2016-12-06 Ablynx N.V. Amino acid sequences directed against GPCRS and polypeptides comprising the same for the treatment of GPCR-related diseases and disorders
WO2010054006A1 (en) * 2008-11-04 2010-05-14 Chemocentryx, Inc. Modulators of cxcr7
US8853202B2 (en) * 2008-11-04 2014-10-07 Chemocentryx, Inc. Modulators of CXCR7
US20110014121A1 (en) * 2008-11-04 2011-01-20 Chemocentryx, Inc. Modulators of cxcr7
US20110229471A1 (en) 2008-11-26 2011-09-22 Cedars-Sinai Medical Center Methods of determining responsiveness to anti-tnf alpha therapy in inflammatory bowel disease
WO2010075579A2 (en) 2008-12-24 2010-07-01 Cedars-Sinai Medical Center Methods of predicting medically refractive ulcerative colitis (mr-uc) requiring colectomy
WO2011117423A1 (en) * 2010-03-26 2011-09-29 Ablynx N.V. Immunoglobulin single variable domains directed against cxcr7
US20150158948A9 (en) 2011-03-28 2015-06-11 Francis Descamps Bispecific anti-cxcr7 immunoglobulin single variable domains
WO2014085490A1 (en) 2012-11-29 2014-06-05 Chemocentryx, Inc. Cxcr7 antagonists
BR112015024752A2 (pt) 2013-03-27 2017-07-18 Cedars Sinai Medical Center mitigação e reversão da fibrose e inflamação através da inibição da função de tl1a e vias de sinalização relacionadas
EP4105236A1 (en) 2013-07-19 2022-12-21 Cedars-Sinai Medical Center Anti-tl1a (tnfsf15) antibody for treatment of inflammatory bowel disease
WO2017040520A1 (en) 2015-08-31 2017-03-09 Hitachi Chemical Co., Ltd. Molecular methods for assessing urothelial disease
KR102464372B1 (ko) 2016-03-17 2022-11-04 세다르스-신나이 메디칼 센터 Rnaset2를 통한 염증성 장 질환의 진단 방법
AU2019398198A1 (en) 2018-12-12 2021-07-08 Chemocentryx, Inc. CXCR7 inhibitors for the treatment of cancer
CN111593022B (zh) * 2018-12-27 2023-10-24 广州溯原生物科技股份有限公司 vMIP-Ⅱ诱导CD8+ T细胞去磷酸化为Tcm及其在药物中的应用

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4166452A (en) * 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4217344A (en) 1976-06-23 1980-08-12 L'oreal Compositions containing aqueous dispersions of lipid spheres
US4256108A (en) * 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4186183A (en) 1978-03-29 1980-01-29 The United States Of America As Represented By The Secretary Of The Army Liposome carriers in chemotherapy of leishmaniasis
US4261975A (en) 1979-09-19 1981-04-14 Merck & Co., Inc. Viral liposome particle
US4265874A (en) * 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
US4485054A (en) 1982-10-04 1984-11-27 Lipoderm Pharmaceuticals Limited Method of encapsulating biologically active materials in multilamellar lipid vesicles (MLV)
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4946787A (en) 1985-01-07 1990-08-07 Syntex (U.S.A.) Inc. N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US5506337A (en) 1985-03-15 1996-04-09 Antivirals Inc. Morpholino-subunit combinatorial library and method
US4774085A (en) 1985-07-09 1988-09-27 501 Board of Regents, Univ. of Texas Pharmaceutical administration systems containing a mixture of immunomodulators
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US4927838A (en) * 1987-07-10 1990-05-22 Hoffman-La Roche Inc. Pyridine compounds which are useful in treating a disease state characterized by an excess of platelet activating factors
US5010175A (en) 1988-05-02 1991-04-23 The Regents Of The University Of California General method for producing and selecting peptides with specific properties
IE66205B1 (en) 1990-06-14 1995-12-13 Paul A Bartlett Polypeptide analogs
US5650489A (en) 1990-07-02 1997-07-22 The Arizona Board Of Regents Random bio-oligomer library, a method of synthesis thereof, and a method of use thereof
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
US5288514A (en) 1992-09-14 1994-02-22 The Regents Of The University Of California Solid phase and combinatorial synthesis of benzodiazepine compounds on a solid support
US5519134A (en) 1994-01-11 1996-05-21 Isis Pharmaceuticals, Inc. Pyrrolidine-containing monomers and oligomers
US5593853A (en) 1994-02-09 1997-01-14 Martek Corporation Generation and screening of synthetic drug libraries
US5539083A (en) 1994-02-23 1996-07-23 Isis Pharmaceuticals, Inc. Peptide nucleic acid combinatorial libraries and improved methods of synthesis
US5525735A (en) 1994-06-22 1996-06-11 Affymax Technologies Nv Methods for synthesizing diverse collections of pyrrolidine compounds
US5549974A (en) 1994-06-23 1996-08-27 Affymax Technologies Nv Methods for the solid phase synthesis of thiazolidinones, metathiazanones, and derivatives thereof
US6537764B1 (en) * 1995-01-19 2003-03-25 Children's Medical Center Corporation Method of identifying inhibitors of C—C chemokine receptor 3
US5569588A (en) 1995-08-09 1996-10-29 The Regents Of The University Of California Methods for drug screening
SE9600820D0 (sv) * 1996-03-01 1996-03-01 Pharmacia Ab Antibodies and their use
GB9712818D0 (en) * 1996-07-08 1997-08-20 Cambridge Antibody Tech Labelling and selection of specific binding molecules
EP0925358B1 (en) 1996-09-10 2007-04-25 Theodor-Kocher Institute Cxcr3 chemokine receptor, antibodies, nucleic acids, and methods of use
US6140064A (en) * 1996-09-10 2000-10-31 Theodor-Kocher Institute Method of detecting or identifying ligands, inhibitors or promoters of CXC chemokine receptor 3
US5876946A (en) * 1997-06-03 1999-03-02 Pharmacopeia, Inc. High-throughput assay
EP0897980A3 (en) 1997-08-20 2002-04-17 Smithkline Beecham Corporation CXCR4B: A human splice variant of CXCR4 chemokine receptor
CA2242308A1 (en) * 1997-12-08 1999-06-08 Smithkline Beecham Laboratoires Pharmaceutiques Novel compounds
US6306653B1 (en) * 1998-01-20 2001-10-23 Codon Diagnostics, Llc Detection and treatment of breast disease
WO1999047158A2 (en) * 1998-03-13 1999-09-23 The University Of British Columbia Therapeutic chemokine receptor antagonists
DE1068357T1 (de) 1998-03-30 2001-07-19 Northwest Biotherapeutics Inc Therapeutische und diagnostische anwendungen welche auf der rolle von cxcr-4 in der tumorgenese basieren
US6287765B1 (en) * 1998-05-20 2001-09-11 Molecular Machines, Inc. Methods for detecting and identifying single molecules
US6329510B1 (en) * 1999-01-29 2001-12-11 Millennium Pharmaceuticals, Inc. Anti-CCR1 antibodies and methods of use therefor
US6329159B1 (en) * 1999-03-11 2001-12-11 Millennium Pharmaceuticals, Inc. Anti-GPR-9-6 antibodies and methods of identifying agents which modulate GPR-9-6 function
US6365356B1 (en) * 1999-03-17 2002-04-02 Cornell Research Foundation, Inc. Receptors that regulate cell signaling relating to chemokines
JP2003502282A (ja) * 1999-04-08 2003-01-21 ザ ゼネラル ホスピタル コーポレーション ヒト転移性細胞の作用因子源から離れた意図された移動
US20020061599A1 (en) * 1999-12-30 2002-05-23 Elling Christian E. Method of identifying ligands of biological target molecules
WO2001058916A2 (en) * 2000-02-09 2001-08-16 Human Genome Sciences, Inc. Antibodies to ccr5
US20020064770A1 (en) * 2000-03-21 2002-05-30 Nestor John J. Binding compounds and methods for identifying binding compounds
KR20080023768A (ko) 2000-03-30 2008-03-14 화이트헤드 인스티튜트 포 바이오메디칼 리서치 Ｒｎａ 간섭의 ｒｎａ 서열 특이적인 매개체
WO2002000728A2 (en) * 2000-06-26 2002-01-03 Gpc Biotech Inc. Methods and compositions for isolating biologically active antibodies
US7413866B2 (en) * 2001-11-30 2008-08-19 Chemocentryx, Inc. Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors
US7442512B2 (en) * 2001-11-30 2008-10-28 Chemocentryx, Inc. Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors
US7253007B2 (en) * 2001-11-30 2007-08-07 Chemocentryx, Inc. Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors
AU2002358469A1 (en) * 2001-12-21 2003-07-15 7Tm Pharma A/S Modified receptors for the discovery of therapeutic ligands
JP4870357B2 (ja) * 2002-12-20 2012-02-08 ケモセントリックス， インコーポレイテッド ヒト腫瘍発現ｃｃｘｃｋｒ２の阻害剤
US20060275769A1 (en) * 2003-01-06 2006-12-07 Oregon Health & Science University Methods of treatment and diagnosis of kaposi's sarcoma (ks) and ks related diseases
US9405700B2 (en) 2010-11-04 2016-08-02 Sonics, Inc. Methods and apparatus for virtualization in an integrated circuit
TWI552751B (zh) 2011-06-20 2016-10-11 Ｈ 朗德貝克公司 投予４－（（１ｒ，３ｓ）－６－氯－３－苯基－二氫茚－１－基）－１，２，２－三甲基－哌及其鹽用於治療精神分裂症的方法

Similar Documents

Publication Publication Date Title
JP2007514651A5 (ja)
NZ600828A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
JP2009540803A5 (ja)
Luo et al. SOMAscan proteomics identifies serum biomarkers associated with liver fibrosis in patients with NASH
JP2016519285A5 (ja)
JP2004532839A5 (ja)
JP2011517341A (ja) 小細胞肺癌バイオマーカーパネル
JP2012522756A5 (ja)
Ye et al. The association of renin-angiotensin system genes with the progression of hepatocellular carcinoma
JP2010521655A5 (ja)
JP2010516678A5 (ja)
JP2012518163A5 (ja)
US20200096523A1 (en) Biomarkers of fast progression of chronic kidney disease
WO2008012362A3 (en) New protein isoforms and uses thereof
US20170321277A1 (en) Methods and compositions for diagnosis and management of diabetes and metabolic syndrome
JP2010521418A5 (ja)
WO2012098219A1 (en) Methods and kits for predicting the risk of respiratory failure, renal failure or thrombopenia in a septic patient by measuring endocan levels in blood
KR20170013261A (ko) 폐 고혈압 바이오마커
Anastasiou et al. Higher thyroid-stimulating hormone, triiodothyronine and thyroxine values are associated with better outcome in acute liver failure
EP2267458A3 (en) Methods, compositions and compound assays for inhibiting amyloid-beta protein production
TW201028480A (en) Detection of unhealthy cell and uses thereof
NZ598035A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
JP2009517381A5 (ja)
JP2008538508A5 (ja)
Kim et al. Serum cytokines markers in toluene diisocyanate-induced asthma